Evansville-based Berry Global Group Inc. (NYSE: BERY) is planning to establish a second manufacturing facility and global healthcare center in Bangalore, India. Berry says the facility, which is planned for development near its existing Bangalore operation, will enable the company to extend its R&D expertise and scale up production in several key healthcare sectors.
Berry says the increased capacity will also enhance supply in India and throughout South Asia.
“Investing in our global healthcare business in Bangalore is a significant step in supporting our pharmaceutical, over-the-counter, and medical device customers aligned to forecasted market needs,” remarked Tom Salmon, Berry Global’s chief executive officer. “During the pandemic, we’ve learned that strategically placed facilities across the world provide efficient localized support for customers of any size. We believe this investment significantly benefits the India and South Asia patient populations.”
Berry says it will also continue to focus on its inhalation devices, including models with digital capabilities and injectable devices. The company is also planning to focus on introducing innovations in nasal and ophthalmic spray pumps and healthcare packaging for various products.
The facility will also house a dedicated R&D Center of Excellence.
“We have built a strong reputation here for the quality and reliability of our products and service,” said Jean-Marc Galvez, president of Berry Global CPI. “Our customers trust us and want to partner with us. We are repaying their faith with the building of this new facility to enhance our levels of support and help them deliver the best experience to the patient.”
Construction of the new facility is expected to begin later this year. Berry says the site will be ready for production by the summer of 2023.